J&J and Leg­end say Carvyk­ti im­proved sur­vival in ear­li­er-line mul­ti­ple myelo­ma

In a late-stage study, John­son & John­son and Leg­end Biotech’s CAR-T ther­a­py Carvyk­ti im­proved sur­vival in mul­ti­ple myelo­ma pa­tients who had re­ceived one to three …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER